Clinical trial · Interventional
Pectoral Nerve Blockade in Mastectomy
Improvement of Analgesia With Addition of Pectoral Nerve Block to Thoracic Paravertebral Blocks in Unilateral Total Simple Mastectomy
NCT01943240CI-TRIAL-00024472withdrawnPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Insufficient population of eligible patients; none enrolled
Summary
Brief summary (as posted)
Our routine practice for patients undergoing mastectomy is to include paravertebral peripheral nerve blockade for postoperative analgesia. This study investigates whether the addition of another nerve block targeting the pectoral nerves will improve that analgesia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Postoperative Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 10 cc of 0.375% ropivacaine pectoral nerve block | Drug | — | UNRESOLVED |
| Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group A
- description
- Paravertebral peripheral nerve blockade with with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of 0.375% ropivacaine for pectoral nerve block
- interventionNames
- Drug: Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels
- Drug: 10 cc of 0.375% ropivacaine pectoral nerve block
- type
- ACTIVE_COMPARATOR
- label
- Group S
- description
- Paravertebral peripheral nerve blockade with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of normal saline for pectoral nerve block.
- interventionNames
- Drug: Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 years and older * Able to provide own consent * Simple mastectomy at University of New Mexico Hospital without planned axillary surgery Exclusion Criteria: * Spinal deformity or pathology * Chest wall deformity or pathology * BMI \>40 * Bilateral simple mastectomy * Refusal of regional anesthesia * Chronic pain * History of recent drug or alcohol abuse * History of recent psychiatric problems * Allergies to lidocaine or ropivacaine * Allergies to fentanyl or hydromorphone * Surgery that extends beyond the original plan to include axillary exposure
References
Publications (0)
Data not yet available
No reference posted for this study.